GRANULES vs PPLPHARMA: Stock Comparison

GRANULES INDIA vs PIRAMAL PHARMAUpdated 8 Oct 26, 4:08 PM ISTNSE & company filings

PIRAMAL PHARMA is the larger company by market capitalisation. GRANULES INDIA shows a higher ROE, a higher dividend yield and faster revenue growth, while PIRAMAL PHARMA shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

GRANULES leads 10; PPLPHARMA leads 3 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

GRANULESPPLPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹22,150 Cr
₹26,121 Cr
P/E RatioPPLPHARMA has the lower reading
30.11x
0x ✓
P/B RatioPPLPHARMA has the lower reading
3.96x
3.19x ✓
EPSGRANULES has the higher reading
₹7.26 ✓
₹-0.52
Book ValueContext only
₹205.21
₹61.31
Dividend YieldGRANULES has the higher reading
0.22% ✓
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
PPLPHARMA is the larger company
₹26,121 Cr vs ₹22,150 Cr
P/E Ratio
PPLPHARMA has a lower P/E
0x vs 30.11x
P/B Ratio
PPLPHARMA has a lower P/B
3.19x vs 3.96x
EPS
GRANULES has higher earnings per share
₹7.26 vs ₹-0.52
Dividend Yield
GRANULES has a higher dividend yield
0.22% vs 0%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs -0.1%
EPS Growth (TTM YoY)
GRANULES has faster EPS growth
31.3% vs 0%
Qtr Sales Growth
PPLPHARMA has stronger quarterly sales growth
101.78% vs 84.16%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGRANULESPPLPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGRANULESPPLPHARMA
Live Price₹815.05₹196.43
Day Change-3.58%-3.24%
Volume6.71 L18.97 L
52-Week High₹923.65₹231.93
52-Week Low₹529.85₹132.3
Distance from 52W High-11.76%-15.31%

Valuation

MetricGRANULESPPLPHARMA
Market Cap₹22,150 Cr₹26,121 Cr
P/E Ratio30.11x0x
P/B Ratio3.96x3.19x
EPS₹7.26₹-0.52
Book Value₹205.21₹61.31
Dividend Yield0.22%0%

Growth

MetricGRANULESPPLPHARMA
Revenue Growth (TTM YoY)22.8%-0.1%
EPS Growth (TTM YoY)31.3%0%
Qtr Sales Growth84.16%101.78%
Qtr Profit Growth150.83%-161.15%

Profitability & Leverage

MetricGRANULESPPLPHARMA
ROE11.7%-3.99%
ROCE12.47%0.86%
Net Margin11.15%-3.68%
Operating Margin16.76%1.21%
Debt to Equity0.26x0.67x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricGRANULESPPLPHARMA
Promoter Holding37.08%▼ 0.59 pp34.8%▼ 0.06 pp
FII Holding20.29%▲ 2.79 pp12.52%▼ 17.66 pp
DII Holding15.4%▼ 0.71 pp14.57%▼ 1.04 pp
Public Holding26.93%▼ 1.45 pp37.63%▲ 18.62 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GRANULES INDIA and PIRAMAL PHARMA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.